RESUMEN
OBJECTIVE: The aim of the study was to show the importance of developing techniques that could exploit the potential of bacteriophages as therapeutics or food supplements. MATERIALS AND METHODS: PubMed database was searched using the following combination of keywords: (bacteriophage) AND (human therapy); (natural bacteriophage) AND (application). RESULTS: The increasing antibiotic resistance of many bacterial strains is making standard antibiotic treatments less effective. Phage therapy provides a non-antibiotic alternative with greater specificity and without harmful effects on the human microbiota. Phages target their specific bacteria, replicate, and then, destroy the host pathogen. Bacteriophages may be administered by several routes, including topical, oral and intravenous. They not only destroy the host pathogen but, in some cases, increase the sensitivity of host bacteria to antibiotics. Various studies have shown that combining phage therapy and antibiotic treatment can be effective against bacterial infections. Clinical trials of phage therapy have shown promising results for various human diseases and conditions. With advances in genetic engineering and molecular techniques, bacteriophages will be able to target a wide range of bacteria. CONCLUSIONS: In the future, phage therapy promises to become an effective therapeutic option for bacterial infections. Since many potentially beneficial bacteriophages can be found in food, supplements containing bacteriophages could be designed to remodel gut microbiota and eliminate pathogenic bacteria. Remodeling of gut microbiota could correct gut dysbiosis. The order of phages known to have these promising activities is Caudovirales, especially the families Siphoviridae and Myoviridae.
Asunto(s)
Infecciones Bacterianas/terapia , Bacteriófagos , Terapia de Fagos/métodos , Infecciones Bacterianas/fisiopatología , Infecciones Bacterianas/virología , Bacteriófagos/aislamiento & purificación , Bacteriófagos/fisiología , Técnicas de Cultivo/métodos , Técnicas de Cultivo/tendencias , Disbiosis/fisiopatología , Disbiosis/terapia , Disbiosis/virología , Microbioma Gastrointestinal/fisiología , Humanos , Terapia de Fagos/tendenciasRESUMEN
The increasing prevalence and worldwide distribution of multidrug-resistant bacterial pathogens is an imminent danger to public health and threatens virtually all aspects of modern medicine. Particularly concerning, yet insufficiently addressed, are the members of the Burkholderia cepacia complex (Bcc), a group of at least twenty opportunistic, hospital-transmitted, and notoriously drug-resistant species, which infect and cause morbidity in patients who are immunocompromised and those afflicted with chronic illnesses, including cystic fibrosis (CF) and chronic granulomatous disease (CGD). One potential solution to the antimicrobial resistance crisis is phage therapy-the use of phages for the treatment of bacterial infections. Although phage therapy has a long and somewhat checkered history, an impressive volume of modern research has been amassed in the past decades to show that when applied through specific, scientifically supported treatment strategies, phage therapy is highly efficacious and is a promising avenue against drug-resistant and difficult-to-treat pathogens, such as the Bcc. In this review, we discuss the clinical significance of the Bcc, the advantages of phage therapy, and the theoretical and clinical advancements made in phage therapy in general over the past decades, and apply these concepts specifically to the nascent, but growing and rapidly developing, field of Bcc phage therapy.
Asunto(s)
Complejo Burkholderia cepacia/efectos de los fármacos , Terapia de Fagos/métodos , Terapia de Fagos/tendencias , Bacteriófagos/genética , Bacteriófagos/metabolismo , Complejo Burkholderia cepacia/metabolismo , Complejo Burkholderia cepacia/patogenicidad , HumanosRESUMEN
Antibiotic resistance is a major public health challenge worldwide, whose implications for global health might be devastating if novel antibacterial strategies are not quickly developed. As natural predators of bacteria, (bacterio)phages may play an essential role in escaping such a dreadful future. The rising problem of antibiotic resistance has revived the interest in phage therapy and important developments have been achieved over the last years. But where do we stand today and what can we expect from phage therapy in the future? This is the question we set to answer in this review. Here, we scour the outcomes of human phage therapy clinical trials and case reports, and address the major barriers that stand in the way of using phages in clinical settings. We particularly address the potential of phage resistance to hinder phage therapy and discuss future avenues to explore the full capacity of phage therapy.
Asunto(s)
Bacterias/virología , Bacteriófagos/fisiología , Terapia de Fagos/tendencias , Antibacterianos/uso terapéutico , Ensayos Clínicos como Asunto , Farmacorresistencia Bacteriana , HumanosRESUMEN
The spread of antimicrobial resistant bacterial pathogens combined with the lack of new drug classes in the antibiotic pipeline causes a resurgence of the use of bacterial viruses (phages) to treat bacterial infections (phage therapy [PT]). There has been a substantial increase in patients subjected to this experimental therapy and emergence of new PT centers in Europe and the United States paralleled by one clinical trial completed in accord with good medical practice (GMP) requirements and a few others underway. What is more, evidence has been accumulating to suggest that phages can also exert anti-inflammatory and immunomodulatory action which opens new pathways for the development of novel targets for PT. Here we present the status quo of the PT, recent regulatory, and clinical developments as well as new perspectives for its wider application in clinical medicine.
Asunto(s)
Terapia de Fagos/tendencias , Animales , Bacterias/virología , Bacteriófagos/fisiología , Ensayos Clínicos como Asunto , Farmacorresistencia Bacteriana , HumanosRESUMEN
This paper surveys some of the important insights that molecular evolution has contributed to evolutionary medicine; they include phage therapy, cancer biology, helminth manipulation of the host immune system, quality control of gametes, and pathogen outbreaks. Molecular evolution has helped to revolutionize our understanding of cancer, of autoimmune disease, and of the origin, spread, and pathogenesis of emerging diseases, where it has suggested new therapies, illuminated mechanisms, and revealed historical processes: all have practical therapeutic implications. While much has been accomplished, much remains to be done.
Asunto(s)
Biología/tendencias , Medicina/tendencias , Animales , Evolución Biológica , Evolución Molecular , Helmintos/inmunología , Humanos , Neoplasias/metabolismo , Terapia de Fagos/tendenciasRESUMEN
BACKGROUND: Bacteriophages are viruses, which are obligate parasites of specific bacteria for the completion of their lifecycle. Bacteriophages could be the possible alternative to antibioticresistant bacterial diseases. With this objective, extensive research in different fields is published which are discussed in this article. METHODS: After a review of bacteriophage therapy, bacteriophages were found to be effective against the multidrug-resistant bacteria individually or synergistically with antibiotics. They were found to be more effective, even better than the bacteria in the development of a vaccine. RESULTS: Apart from the bacteriophages, their cell contents like Lysin enzymes were found equally very much effective. Only the major challenge faced in phage therapy was the identification and characterization of bacteria-specific phages due to the wide genetic diversity of bacterial populations. Similarly, the threshold level of bacteriophages to act effectively was altered by ultraviolet radiation and heat exposure. CONCLUSION: Thus, bacteriophage therapy offers promising alternatives in the treatment of antibioticresistant bacteria in different fields. However, their effectiveness is determined by a triad of bacteriophages (type & quantity), host (bacteria) and environmental factors.
Asunto(s)
Infecciones Bacterianas/tratamiento farmacológico , Bacteriófagos/crecimiento & desarrollo , Farmacorresistencia Bacteriana Múltiple , Terapia de Fagos/métodos , Terapia de Fagos/tendencias , Tecnología Farmacéutica/métodos , Animales , Bacteriófagos/efectos de la radiación , Ensayos Clínicos como Asunto , Calor , Humanos , Rayos UltravioletaRESUMEN
BACKGROUND: The gut microbiota plays an important role in the pathogenesis of several gastrointestinal diseases. Its composition and function are shaped by host-microbiota and intra-microbiota interactions. Bacteriophages (phages) are viruses that target bacteria and have the potential to modulate bacterial communities. AIMS: To summarise phage biology and the clinical applications of phages in gastroenterology METHODS: PubMed was searched to identify relevant studies. RESULTS: Phages induce bacterial cell lysis, integration of viral DNA into the bacteria and/or coexistence in a stable equilibrium. Bacteria and phages have co-evolved and their dynamic interactions are yet to be fully understood. The increasing need to modulate microbial communities (e.g., gut microbiota, multidrug-resistant bacteria) has been a strong stimulus for research in phages as an antibacterial therapy. In gastroenterology, phage therapy has been mainly studied in infectious diseases such as cholera. However, it is currently being explored in several other circumstances such as treating Clostridioides difficile colitis, targeting adherent-invasive Escherichia coli in Crohn's disease or eradicating Fusobacterium nucleatum in colorectal cancer. Overall, phage therapy has a favourable and acceptable safety profile. Presently, trials with phage therapy are ongoing in Crohn's disease. CONCLUSIONS: Phage therapy is a promising therapeutic tool against pathogenic bacteria in the fields of infectious diseases and gastroenterology. Randomised, placebo-controlled trials with phage therapy for gastroenterological diseases are ongoing.
Asunto(s)
Bacteriófagos/fisiología , Gastroenterología , Enfermedades Gastrointestinales/terapia , Terapia de Fagos , Antibacterianos/aislamiento & purificación , Antibacterianos/uso terapéutico , Bacterias/virología , Fenómenos Fisiológicos Bacterianos , Farmacorresistencia Bacteriana Múltiple/fisiología , Gastroenterología/métodos , Gastroenterología/tendencias , Enfermedades Gastrointestinales/microbiología , Microbioma Gastrointestinal/fisiología , Humanos , Terapia de Fagos/métodos , Terapia de Fagos/tendenciasRESUMEN
This special issue of Viruses asks experts in the field about "Hurdles to phage therapy (PT) to become a reality" [...].
Asunto(s)
Infecciones Bacterianas/terapia , Investigación Biomédica/tendencias , Terapia de Fagos/métodos , Terapia de Fagos/tendencias , Animales , Aprobación de Drogas , Evaluación Preclínica de Medicamentos/métodos , HumanosRESUMEN
Initially described a century ago by William Twort and Felix d'Herelle, bacteriophages are bacterial viruses found ubiquitously in nature, located wherever their host cells are present. Translated literally, bacteriophage (phage) means 'bacteria eater'. Phages interact and infect specific bacteria while not affecting other bacteria or cell lines of other organisms. Due to the specificity of these phage-host interactions, the relationship between phages and their host cells has been the topic of much research. The advances in phage biology research have led to the exploitation of these phage-host interactions and the application of phages in the agricultural and food industry. Phages may provide an alternative to the use of antibiotics, as it is well known that the emergence of antibiotic-resistant bacterial infections has become an epidemic in clinical settings. In agriculture, pre-harvest and/or post-harvest application of phages to crops may prevent the colonisation of bacteria that are detrimental to plant or human health. In addition, the abundance of data generated from genome sequencing has allowed the development of phage-derived bacterial detection systems of foodborne pathogens. This review aims to outline the specific interactions between phages and their host and how these interactions may be exploited and applied in the food industry.
Asunto(s)
Bacterias/virología , Bacteriófagos/crecimiento & desarrollo , Interacciones Microbiota-Huesped , Agricultura/métodos , Agricultura/tendencias , Industria de Alimentos/métodos , Industria de Alimentos/tendencias , Terapia de Fagos/métodos , Terapia de Fagos/tendenciasRESUMEN
Bacteriophages or phages, being the most abundant entities on earth, represent a potential solution to a diverse range of problems. Phages are successful antibacterial agents whose use in therapeutics was hindered by the discovery of antibiotics. Eventually, because of the development and spread of antibiotic resistance among most bacterial species, interest in phage as therapeutic entities has returned, because their noninfectious nature to humans should make them safe for human nanomedicine. This review highlights the most recent advances and progress in phage therapy and bacterial hosts against which phage research is currently being conducted with respect to food, human, and marine pathogens. Bacterial immunity against phages and tactics of phage revenge to defeat bacterial defense systems are also summarized. We have also discussed approved phage-based products (whole phage-based products and phage proteins) and shed light on their influence on the eukaryotic host with respect to host safety and induction of immune response against phage preparations. Moreover, creation of phages with desirable qualities and their uses in cancer treatment, vaccine production, and other therapies are also reviewed to bring together evidence from the scientific literature about the potentials and possible utility of phage and phage encoded proteins in the field of therapeutics and industrial biotechnology.
Asunto(s)
Enfermedades Transmisibles/terapia , Microbiología de Alimentos , Inocuidad de los Alimentos/métodos , Terapia de Fagos/métodos , Animales , Bacteriófagos/inmunología , Bacteriófagos/patogenicidad , Enfermedades Transmisibles/veterinaria , Humanos , Nanomedicina/métodos , Nanomedicina/tendencias , Terapia de Fagos/tendencias , Proteínas Virales/inmunologíaRESUMEN
Phage therapy, long overshadowed by chemical antibiotics, is garnering renewed interest in Western medicine. This stems from the rise in frequency of multi-drug-resistant bacterial infections in humans. There also have been recent case reports of phage therapy demonstrating clinical utility in resolving these otherwise intractable infections. Nevertheless, bacteria can readily evolve phage resistance too, making it crucial for modern phage therapy to develop strategies to capitalize on this inevitability. Here, we review the history of phage therapy research. We compare and contrast phage therapy and chemical antibiotics, highlighting their potential synergies when used in combination. We also examine the use of animal models, case studies, and results from clinical trials. Throughout, we explore how the modern scientific community works to improve the reliability and success of phage therapy in the clinic and discuss how to properly evaluate the potential for phage therapy to combat antibiotic-resistant bacteria.
Asunto(s)
Infecciones Bacterianas/terapia , Terapia de Fagos/métodos , Investigación Biomédica/tendencias , Humanos , Terapia de Fagos/tendenciasRESUMEN
Bacteriophages (phages/viruses) need host bacteria to replicate and propagate. Primarily, a bacteriophage contains a head/capsid to encapsidate the genetic material. Some phages contain tails. Phages encode endolysins to hydrolyze bacterial cell wall. The two main classes of phages are lytic or virulent and lysogenic or temperate. In comparison with antibiotics, to deal with bacterial infections, phage therapy is thought to be more effective. In 1921, the use of phages against bacterial infections was first demonstrated. Later on, in humans, phage therapy was used to treat skin infections caused by Pseudomonas species. Furthermore, phages were successfully employed against infections in animals - calves, lambs, and pigs infected with Escherichia coli. In agriculture, for instance, phages have successfully been used e.g., Apple blossom infection, caused by Erwinia amylovora, was effectively catered with the use of bacteriophages. Bacteriophages were also used to control E. coli, Salmonella, Listeria, and Campylobacter contamination in food. Comparatively, phage display is a recently discovered technology, whereby, bacteriophages play a significant role. This review is an effort to collect almost recent and relevant information regarding applications and complications associated with the use of bacteriophages.
Asunto(s)
Infecciones Bacterianas/terapia , Bacteriófagos/fisiología , Terapia de Fagos , Agricultura , Enfermedades de los Animales/microbiología , Enfermedades de los Animales/terapia , Animales , Antibacterianos/uso terapéutico , Bacterias/patogenicidad , Bacterias/virología , Bacteriófagos/ultraestructura , Bovinos , ADN Viral , Contaminación de Alimentos/prevención & control , Inocuidad de los Alimentos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Lisogenia/fisiología , Terapia de Fagos/historia , Terapia de Fagos/métodos , Terapia de Fagos/tendencias , Enfermedades de las Plantas/microbiología , Enfermedades de las Plantas/terapia , Ovinos , PorcinosRESUMEN
Antibiotic resistance evolution in bacteria indicates that one of the challenges faced by phage therapy is that, sooner or later, bacteria will evolve resistance to phages. Evidently, this is the case of every known antimicrobial therapy, but here this is also part of a ubiquitous natural process of co-evolution between phages and bacteria. Fundamental evolutionary studies hold some clues that are crucial to limit the problematic process of bacterial resistance during phage applications. First, I discuss here the importance of defining evolutionary and ecological factors influencing bacterial resistance and phage counter-defense mechanisms. Then, I comment on the interest of determining the co-evolutionary dynamics between phages and bacteria that may allow for selecting the conditions that will increase the probability of therapeutic success. I go on to suggest the varied strategies that may ensure the long-term success of phage therapy, including analysis of internal phage parameters and personalized treatments. In practical terms, these types of approaches will define evolutionary criteria regarding how to develop, and when to apply, therapeutic phage cocktails. Integrating this perspective in antimicrobial treatments, such as phage therapy, is among the necessary steps to expand its use in the near future, and to ensure its durability and success.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/terapia , Terapia de Fagos/métodos , Terapia de Fagos/tendencias , Animales , Evolución Biológica , Interacciones Huésped-Parásitos , HumanosRESUMEN
BACKGROUND: Environmentally growing pathogens present an increasing threat for human health, wildlife and food production. Treating the hosts with antibiotics or parasitic bacteriophages fail to eliminate diseases that grow also in the outside-host environment. However, bacteriophages could be utilized to suppress the pathogen population sizes in the outside-host environment in order to prevent disease outbreaks. Here, we introduce a novel epidemiological model to assess how the phage infections of the bacterial pathogens affect epidemiological dynamics of the environmentally growing pathogens. We assess whether the phage therapy in the outside-host environment could be utilized as a biological control method against these diseases. We also consider how phage-resistant competitors affect the outcome, a common problem in phage therapy. The models give predictions for the scenarios where the outside-host phage therapy will work and where it will fail to control the disease. Parameterization of the model is based on the fish columnaris disease that causes significant economic losses to aquaculture worldwide. However, the model is also suitable for other environmentally growing bacterial diseases. RESULTS: Transmission rates of the phage determine the success of infectious disease control, with high-transmission phage enabling the recovery of the host population that would in the absence of the phage go asymptotically extinct due to the disease. In the presence of outside-host bacterial competition between the pathogen and phage-resistant strain, the trade-off between the pathogen infectivity and the phage resistance determines phage therapy outcome from stable coexistence to local host extinction. CONCLUSIONS: We propose that the success of phage therapy strongly depends on the underlying biology, such as the strength of trade-off between the pathogen infectivity and the phage-resistance, as well as on the rate that the phages infect the bacteria. Our results indicate that phage therapy can fail if there are phage-resistant bacteria and the trade-off between pathogen infectivity and phage resistance does not completely inhibit the pathogen infectivity. Also, the rate that the phages infect the bacteria should be sufficiently high for phage-therapy to succeed.
Asunto(s)
Bacteriófagos , Enfermedades Transmisibles/epidemiología , Enfermedades Transmisibles/terapia , Exposición a Riesgos Ambientales/prevención & control , Terapia de Fagos/métodos , Animales , Bacteriófagos/fisiología , Exposición a Riesgos Ambientales/efectos adversos , Humanos , Terapia de Fagos/tendenciasAsunto(s)
Infecciones Bacterianas/terapia , Bacteriófagos/fisiología , Terapia de Fagos/métodos , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/microbiología , Bacteriófagos/genética , Evolución Molecular , Especificidad del Huésped , Interacciones Huésped-Patógeno/genética , Interacciones Huésped-Patógeno/fisiología , Humanos , Terapia de Fagos/tendencias , Medicina de Precisión/métodos , Medicina de Precisión/tendenciasRESUMEN
In this article we explain how current events in the field of phage therapy may positively influence its future development. We discuss the shift in position of the authorities, academia, media, non-governmental organizations, regulatory agencies, patients, and doctors which could enable further advances in the research and application of the therapy. In addition, we discuss methods to obtain optimal phage preparations and suggest the potential of novel applications of phage therapy extending beyond its anti-bacterial action.
Asunto(s)
Terapia de Fagos/tendencias , Animales , Bacterias/virología , Bacteriófagos , Ensayos Clínicos como Asunto , Humanos , Inmunomodulación , Ratones , ProfagosRESUMEN
Phage therapy has an intriguing history. It was widely used from the 1920s until the 1940s. After this period, it was nearly completely forgotten in the Western world, while it continued to be used in the Soviet part of the globe. The study of the history of phage therapy provides valuable input into the present development of the field. Science journalists uncovered much of this history and played an important role in the communication of phage therapy after the fall of the Soviet Union, when it came to the attention of Western researchers and doctors. This interest was fueled by the antibiotic resistance crisis. At this time, communication about phage therapy had a wide potential audience, that encompassed medical experts and researchers, as well as the public, because knowledge about this forgotten therapy was very limited. In such a situation, good communication had and still has the potential to catalyze important discussions among different groups; whereas, bad communication could have considerably hindered and still can hinder the possible renaissance of phage therapy.
Asunto(s)
Periodismo Médico/normas , Terapia de Fagos , Sesgo , Comunicación , Historia del Siglo XX , Humanos , Terapia de Fagos/historia , Terapia de Fagos/tendenciasRESUMEN
The continuous evolvement of bacterial resistance to most, if not all, available antibiotics is a worldwide problem. These strains, frequently isolated from military-associated environments, have created an urgent need to develop supplementary anti-infective modalities. One of the leading directions is phage therapy, which includes the administration of bacteriophages, viruses that specifically target bacteria, as biotherapies. Although neglected in the West until recent years, bacteriophages have been widely studied and clinically administered in the former Soviet Union and Eastern Europe for over a century, where they were found to be incredibly efficient at battling numerous infectious diseases.In this review, we discuss the high potential of phage therapy as a solution for resistant bacterial infectious diseases relating to military medicine. By describing the historical development and knowledge acquired on phage therapy, we define the advantages of bacteriophages for combating resistant bacteria in multiple settings, such as trauma injuries and foodborne illnesses, as a preventive tool and therapy against biological warfare agents, and more. We also present the most recent successful clinical applications of bacteriophages in military settings worldwide.We believe that augmenting military medicine by integrating phage therapy is an important and required step in preparedness for the rapidly approaching post-antibiotic era.
Asunto(s)
Medicina Militar , Terapia de Fagos , Infecciones Bacterianas/historia , Infecciones Bacterianas/terapia , Bacteriófagos , Predicción , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Medicina Militar/historia , Medicina Militar/métodos , Medicina Militar/tendencias , Terapia de Fagos/historia , Terapia de Fagos/métodos , Terapia de Fagos/tendencias , Infección de Heridas/terapiaAsunto(s)
Ciencia/tendencias , Astronautas , Astronomía/tendencias , Cambio Climático , Ensayos Clínicos como Asunto , ADN Antiguo , Farmacorresistencia Microbiana , Unión Europea/organización & administración , Edición Génica/tendencias , Genómica/tendencias , Migración Humana , Humanos , Indígenas Norteamericanos/genética , Células Madre Pluripotentes Inducidas/trasplante , Luna , Neoplasias/genética , Publicación de Acceso Abierto/tendencias , Enfermedad de Parkinson/patología , Enfermedad de Parkinson/terapia , Terapia de Fagos/tendencias , Física , Política , Vuelo Espacial/tendencias , SincrotronesRESUMEN
Dental diseases are perhaps the most prevalent infection-related diseases in humans. Biofilm is involved in almost every infectious disease compromising oral health, notably caries, periodontal disease, gingivitis, endodontic infections and peri-implantitis. Current therapies of biofilm-derived oral infections lack sensitivity; they are not species-specific and kill pathogenic species as well as commensal species, which are protective against the formation of pathogenic biofilms. Moreover, antibiotics have a limited effect on biofilm and are almost unused in oral diseases. A promising alternative approach is bacteriophage (phage) therapy. Phages play a key role in the natural balance in a predator-prey relationship with bacteria and thus have the potential to be efficient anti-bacterial agents. Phages are highly efficient against biofilm, strain specific and easy to isolate and manipulate. Thus, like in many other medicinal fields, phage therapy offers new horizons to dentistry, both therapeutics and research. The present review presents the etiology of common oral diseases, characterization of the infection and the treatment challenges of phage therapy in dentistry. Recent findings and development in the use of phages for prevention, control, and treatment of oral infections as well as possibilities of engineering the oral microbiome are discussed.